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Abstract Tyrosinase is the key enzyme in pigment synthesis, 
initiating a cascade of reactions which convert the amino acid 
tyrosine to the melanin biopolymer. Two other tyrosinase-related 
proteins (TRP) are known, TRP-1 (probably DHICAoxidase) 
and TRP-2 (DOPAchrome tautomerase). These proteins show 
about 40% homology, and recent results have indicated that the 
genes might be derived from a common ancestor. We will discuss 
recent findings on genomic organization, and on the proteins and 
their presumed function, which is important for eumelanin 
synthesis in mouse and man. 
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1. Introduction 
lix-loop-helix family, can bind to the M box and is able to 
activate transcription of tyrosinase and TRP-1 in cell culture 
[8,9]. 
All the three proteins contain a signal peptide, a transmem- 
brane domain, and histidine- and cysteine-rich sequences (Fig. 
2). They might interact and participate in a multimeric om- 
plex of 200-700 kDa [10] which is possibly mediated by the 
cystein-rich sequences described as EGF repeat [11]. The his- 
tidine-rich regions are regarded as copper-binding sites in tyr- 
osinase [12,13] and are, therefore, presumably implicated in 
the metal-binding capacities of the other TRPs. 
The study of the TRPs is not only interesting in the process 
of pigmentation but they are also studied for recognizing and 
fighting melanoma: by their antigenic properties [14-16], as 
an early marker for metastases [17], and by the specificity of 
their promoter that can be used for gene therapy [18]. 
Visible pigmentation i mammals results from the synthesis 
and distribution of melanin in skin, hair bulbs and eyes. At 
the cellular level, melanins are produced in pigment cells (mel- 
anocytes) in a specialized cytoplasmic organelle: the melano- 
some. Two types of melanins are synthesized: pheomelanins 
(yellow, red) and eumelanins (brown, black). Tyrosinase is 
essential in this synthesis, and catalyses 3 different reactions 
(Fig. 1). Two tyrosinase-related proteins (TRP-1 and TRP-2) 
have been characterized and attributed to specific reactions in 
melanin synthesis (Fig. 1). All 3 proteins are related and have 
about 40% amino acid identity with each other [1,2]. 
The genomic organization of the three genes is known in 
both mouse and man, and encompasses between 20 and 60 kb 
[3 5]. The coding region of 1.6 kb is scattered between 5exons 
(tyrosinase), 7 exons (TRP-1) and 8 exons (TRP-2). According 
to the conservation of amino acids, corresponding codons can 
be identified between the three genes. Although the organiza- 
tion of exons and introns is divergent, some positions are 
nevertheless identical, thus suggesting a common ancestral 
gene (Fig. 2) [3,4]. Sequences of the promoter egions were 
compared with identify conserved regulatory elements in- 
volved in pigment cell-specific gene expression. An 11-bp con- 
sensus element, the so-called M box, was first identified in the 
promoters of mouse and human tyrosinase and TRP-1 and is 
also present in the TRP-2 promoter [3,6,7]. The product of the 
microphthalmia gene, a transcription factor of the basic he- 
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2. Tyrosinase (EC1.14.18.1) 
The dramatic lack of pigment produced by c (albino/Tyr) 
locus mutations had suggested for a long time an implication 
of tyrosinase. In mice carrying deletions at the c (Tyr) locus, 
the tyrosinase gene is absent [5]. Introducing the gene into 
cells and back into albino mice induced pigmentation, thus, 
providing the ultimate proof that tyrosinase is encoded at the 
e (Tyr) locus [19,20]. The gene maps to mouse chromosome 7 
and to human chromosome 11 [21]. The tyrosinase gene is 
composed of 5 exons and 4 introns and spans about 60-70 
kb in mouse. The processed mRNAs are approximatively 2.4 
kb in length but splicing is not always accurate and misspliced 
mRNAs are generated and may represent more than 10% of 
the tyrosinase transcripts [5]. These transcripts cannot be 
translated into catalytically competent proteins, but nothing 
is known about their function. Tyrosinase is synthesized as a 
55-kDa protein with an isoelectric point of about 4.2. Follow- 
ing glycosylation, the molecular weight of the mature protein 
shifts to about 65-75 kDa (or even up to 80 kDa) [15,21]. 
Tyrosinase catalyses the hydroxylation of k-tyrosine to 3,4- 
dihydroxyphenylalanine (DOPA) and the oxidation of DOPA 
to DOPAquinone (Fig. 1) [21,22]. DOPA is also a cofactor for 
the first enzymatic reaction, probably interacting with the 
oxidative state of the copper ion [23]. A third enzymatic 
role has been proposed for tyrosinase: the oxidation of 5,6- 
dihydroxyindole to 5,6-dihydroxyquinone [22,24]. However, it 
has also been proposed that this oxidation is performed 
through a peroxidase [25]. Tyrosinase preparations are enzy- 
matically active at a pH range of 5-8, but in vivo the enzyme 
might encounter even lower values due to the acidic intrame- 
lanosomal pH [26]. In human, many mutations in the tyrosi- 
nase gene have been described and are responsible for oculo- 
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Fig. 1. The melanogenic pathway from tyrosine [33,38]. Enzymatic 
reactions attributed to tyrosinase, TRP-1 and TRP-2 are indicated. 
DOPA, 3,4-dihydroxyphenylalanine; DHICA, 5,6-dihydroxyindole- 
2-carboxylic acid; DHI, 5,6-dihydroxyindole. 
cutaneous albinism (type I). The study of these mutations 
unveiled the important catalytic regions of tyrosinase particu- 
larly in the histidine-rich regions that can complex copper 
[27]. 
3. Tyrosinase-related protein-I 
The first cloned pigmentation gene was later mapped to the 
mouse brown (blTyrp) locus, and the protein was named tyr- 
osinase-related protein-l, due to its homology to tyrosinase 
[28]. The gene is located on mouse chromosome 4 and on 
human chromosome 9 [29]. The TRP-1 gene encompasses 8 
exons separated by 7 introns, including the first non-trans- 
lated exon (Fig. 2; [3,4]). The coding sequence itself is 1.6 
kb long, yielding a protein of 537 amino acids, including the 
signal peptide. The mature glycosylated protein has a mole- 
cular weight of about 75 kDa [21,30]. Between human and 
mouse, a high degree of sequence identity is existing in coding 
sequence (> 90%) and the promoter (up to 80%) [3,4,6]. 
The function of TRP-1 is subject of much controversy, and 
it was proposed that TRP-1 shows activity of tyrosinase [31], 
represents another DOPAchrome tautomerase [32] or a mel- 
anosome-specific catalase [30]. Recent experiments on the 
mouse TRP-1 provided evidence that the protein functions 
as DHICAoxidase, a reaction downstream in the melanin 
synthetic pathway (Fig. 1, [31,33]). 
4. Tyrosinase-related protein-2/DOPAehrome tautomerase 
(EC 5.3.2.3) 
The enzyme DOPAchrome tautomerase is involved in the 
conversion of the red compound DOPAchrome to a colorless 
eumelanic intermediate which has been identified as 5,6-dihy- 
droxyindole-5-carboxylic acid (DHICA), and was named suc- 
cessively L-DOPAchrome conversion factor [34], L-DOPA- 
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Fig. 2. The tyrosinase family. (A) Comparison of exon/intron struc- 
ture of tyrosinase, TRP-1 and TRP-2, as identified in human and 
mouse [3,4]. Non-coding parts of the mRNAs are not indicated, as 
the non-coding exon of TRP-1 [6]. Interruptions of phases within 
introns are indicated by numbers, between codons (= 0), and leaving 
either one base (= 1) or two bases (=2) of a codon on the 5' part 
of an intron. Identical positions of introns are indicated. (B) Sche- 
matic representation f the tyrosinase family protein domains, with 
the N-terminus at the left, inside the melanosome, and the C-termi- 
nus at the right, in the cytoplasm [3,4,47]. The N-terminal signal 
peptide is not depicted. Cys, cysteine; Cu, copper(metal)-binding 
sites (histidine-rich). (C) Scheme of the identified mouse mutations 
of the tyrosinase family proteins and their molecular defect. The al- 
bino (c) and brown (b) mutation lead to complete loss of enzymatic 
activity. The other characterized mutations affect pigmentation by 
changes in enzymatic activity [1-3,47,48]. c 44n, dark-eyed albino; c h, 
himalayan; c ch, chinchilla; c p, platinum; B it, light; sit, slaty; Sll h, 
slaty-light. 
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chrome oxidoreductase [35], and L-DOPAchrome isomerase 
[36]. The enzyme has finally been renamed DOPAchrome tau- 
tomerase (Dct), a name which describes more precisely the 
reactions involved [37]. 
In 1992, the molecular cloning of TRP-2 confirmed the 
existence of a third member of the tyrosinase-related protein 
family [11,38]. The coding sequences are 1.6 kb long and are 
distributed on 8 exons (Fig. 2) [3,4]. A common regulatory 
motif, the M box, has equally been identified in the regulatory 
regions of the mouse and human TRP-2 gene [3]. The gene 
maps to the slaty (Tyrp2) locus on mouse chromosome 14 and 
to human chromosome 13 [11,39]. The molecular weight of 
the fully processed protein is about 75 kDa [38]. 
5. TRPs and melanogenesis 
Tyrosinase initiates melanogenesis, but different posttyrosi- 
nase factors interfere to modulate the quantity and quality of 
the pigment produced. DOPAquinone is the key intermediate 
in the formation of pheo- vs. eumelanins and different factors 
are involved in the type of melanin synthesized: sulfhydryl 
compound as precursor of cysteine, MSH (melanocyte-stimu- 
lating hormone) and TRP-1. 
Cysteine interacts non-enzymatically with DOPAquinone to 
form cysteinylDOPA, which is regarded as direct precursor of 
pheomelanin. The kinetics of reaction between sulfhydryl 
compound and DOPAquinone is much more rapid than the 
cyclization of DOPAquinone into LeucoDOPAchrome [40], 
and, thus, the concentrations of cysteine are critical for the 
type of melanin synthetized. 
In mice, mutations at the e (extensionlMclr) locus (encod- 
ing melanocyte-stimulating hormone receptor) and the a 
(agouti) locus (encoding an antagonist of the hormone) mod- 
ulate the pattern of melanogenesis affecting changes in coat 
color [1]. Very recently, it has been shown that variations in 
human MSH receptor (Mc-lr) gene were more frequent in red 
hair individuals than in individuals with black or brown hair 
[41]. Intracellulary, eumelanogenesis might be favored by 
MSH via modulation of tyrosinase, TRP-1 and TRP-2 (Dct) 
activity [42]. 
TRP-1 function and presence is not essential for pigmenta- 
tion in mice but the synthesis of brown rather than black 
eumelanin in mutant mice (brown mutation) indicates an im- 
portant step in the synthesis and regulation of eumelanogen- 
esis. Moreover, in human cell lines, expression of TRP-1 was 
only detectable in cells containing eumelanin [43]. The DHI- 
CA oxidase activity described for TRP-1 implicates this en- 
zyme in the synthesis of eumelanin. Therefore, the chemical 
analysis of the eumelanic polymer, synthesized in the presence 
of TRP-1, will be important for understanding phenotypic 
melanogenic differences. 
Once DOPAchrome is obtained, TRP-2 (DOPAchrome 
tautomerase) or metal ions (as copper or zinc) favor the for- 
mation of DHICA instead of DHI [44]. It has been suggested 
that DHICA- and DHI-derived melanins differ in several 
properties, such as solubility, fiocculence and color [45]. The 
physiological role of TRP-2 is not clear, and there may be 
mutations at the slatylTyrp2 locus that abolish TRP-2 activ- 
ity, such as slaty-light, but this is not known [3,11]. It is even 
possible that slaty and slaty-2J completely abolish TRP-2 ac- 
tivity, and that residual Dct activity is derived from other 
enzymes. In human, case studies of chromosomal deletions 
involving 13q31-q32 have not reported any apparent pigmen- 
tation abnormalities [46]. However, it is possible that TRP-2 
protects the melanocyte against cytotoxicity of decarboxylated 
indolic melanogenic ntermediates by limiting their formation. 
Despite the considerable progress in characterizing the 3 
genes involved in melanogenesis, several questions remain. It 
is not clear whether other enzymes are existing in the eume- 
lanogenic pathway, or whether TRP-1 has other functions 
besides DHICAoxidase. Moreover, the pheomelanogenic 
pathway is largely unknown, and the structure of the final 
melanin polymer is not resolved and might, thus, contain 
both eumelanin and pheomelanin. 
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